Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.

Coskun H. Ş., Goeksu S., ŞAHİN M., Alanoglu G.

Medical oncology (Northwood, London, England), cilt.25, sa.1, ss.110-2, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 25 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1007/s12032-007-0053-5
  • Dergi Adı: Medical oncology (Northwood, London, England)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.110-2
  • Anahtar Kelimeler: CML, imatinib, combination chemotherapy, ACUTE LYMPHOBLASTIC-LEUKEMIA, CYTOGENETIC RESPONSES, KINASE INHIBITION, BLAST CRISIS, CHEMOTHERAPY, THERAPY, INDUCTION
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Imatinib is now indicated as the first line therapy for chronic myeloid leukemia (CML). Treatment of CML with imatinib is generally well tolerated and the risk of severe adverse affects is low. Many new drugs including targeted therapy are combined with antineoplastic agents safely. We here report a patient with CML who developed concurrent mesenchymal tumor while undergoing therapy with imatinib and treated with combination chemotherapy including bleomycin, etoposide, and cisplatin, as well as imatinib without severe toxicity.